COMPARISON
Desmopressin vs Vasopressin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Desmopressin is authorised or registered in 9 and Vasopressin in 7 of the 10 registers read. Desmopressin: highest phase Phase 4 (after approval). Vasopressin: highest phase Phase 4 (after approval). 90 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Desmopressin | Vasopressin | |
|---|---|---|
| Registered trials differs | 131 clinicaltrials.gov · 2026-10-03 | 449 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Desmopressin Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VASOPRESSIN openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Desmopressin | placebo | Vasopressin | placebo |
|---|---|---|---|---|
| Headache | 7.0% | 3.9% | - | - |
| Nausea | 4.9% | 1.3% | - | - |
| Diarrhoea | 4.7% | 2.2% | - | - |
| Nasopharyngitis | 4.2% | 3.1% | - | - |
| Hypertension | 3.3% | 0.7% | - | - |
| Dizziness | 3.2% | 0.4% | - | - |
| Hyponatraemia | 3.1% | 1.2% | - | - |
| Pneumonia | 0.1% | 0.0% | - | - |
| Depression | 0.1% | 0.4% | - | - |
| Diverticulitis | 0.1% | 0.0% | - | - |
Trial register Desmopressin: 8 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Desmopressin side effects · Vasopressin side effects
LEGAL STATUS
Approval in each country read
| Country | Desmopressin | Vasopressin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
90 registered trials include both
| NCT06635629 | Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome RECRUITING · updated 2026-08-31 |
|---|---|
| NCT07576036 | International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (O ENROLLING_BY_INVITATION · updated 2026-08-26 |
| NCT07776977 | Bedtime Device Restriction and Desmopressin in PMNE. RECRUITING · updated 2026-08-24 |
| NCT07712328 | Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors ENROLLING_BY_INVITATION · updated 2026-07-17 |
| NCT06337838 | Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial RECRUITING · updated 2026-05-22 |
| NCT04569591 | DDAVP for Pituitary Adenoma RECRUITING · updated 2026-04-09 |
| NCT07292753 | Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency COMPLETED · updated 2026-03-17 |
| NCT06771128 | Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis COMPLETED · updated 2026-01-13 |
| NCT07199894 | Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE RECRUITING · updated 2025-09-30 |
| NCT06622187 | Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies ENROLLING_BY_INVITATION · updated 2025-09-11 |
| NCT06020495 | Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia RECRUITING · updated 2025-05-23 |
| NCT05467033 | Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin RECRUITING · updated 2025-05-08 |
| NCT06772584 | Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis COMPLETED · updated 2025-01-13 |
| NCT04329975 | Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia) COMPLETED · updated 2024-12-20 |
| NCT05507476 | Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy COMPLETED · updated 2024-10-01 |
| NCT04420585 | Desmopressin for Bedwetting in Children With SCD TERMINATED · updated 2024-05-07 |
| NCT06285006 | Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis UNKNOWN · updated 2024-04-23 |
| NCT04103034 | A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers COMPLETED · updated 2024-03-18 |
| NCT06255366 | Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volu UNKNOWN · updated 2024-03-15 |
| NCT06185361 | Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. UNKNOWN · updated 2023-12-29 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.